How does the Titration Kit simplify dosing for patients?

Instead of initially receiving individual tablets in bottles, patients willhave their first 3 months of Orenitram organized down to the day and individual dose.The Titration Kit contains: Dosing guidance Reminders for patients toknow their exact morning, afternoon, and evening doses of Orenitram over the next 3months This makes titration instructions simple and less prone to errors.

What happens if a patient cannot titrate up to their next dose in theTitration Kit?

Patients should be encouraged to follow the Titration Kit schedule toachieve their target dose. If they are unable to do so, the kit includes enough tablets toadjust and/or maintain the patient’s dose for a limited time.

Who is and is not eligible to start on the Titration Kit?

Who is: De novo patients who are starting Orenitramon a TID dosing schedule for the Titration Kit. Who is not: Patientsnot eligible for the Titration Kit are those who: Are starting Orenitram at a higherdose Require more dosing flexibility than the Titration Kit canaccommodate

Dosing to Meet
Individualized Needs

Assess Risk. Consider Time. Leverage Orenitram.

Reaching a necessary dose exposure is important to achieving clinical improvement, but individual patient needs may vary.¹ Selecting the appropriate dosing approach may help you and your patients reach this goal.

The Orenitram Titration Kit

For intermediate-risk patients—An all-in-one kit that helps simplify the titration process and build confidence as patients work to reach necessary exposure.¹

Transitioning From Remodulin to Orenitram

For hemodynamically and clinically stable patients—An established plan for transitioning appropriate patients from Remodulin^® (treprostinil) Injection to Orenitram.

Did you know that eligible patients may start treatment on the Orenitram Titration Kit at no cost for up to 90 days?

Learn More >

United Therapeutics does not provide medical advice. Adverse effect management strategies should be addressed in accordance with the Orenitram Full Prescribing Information and your clinical judgment.

Dosing and AE Management as a Team

Franck Rahaghi, MD, and Starlet Harrimon, RN, discuss how they work with patients to plan for expected adverse effects with Orenitram.

Dosing With Orenitram

5 tablet strengths for flexible dosing

Multiple tablet strengths provide dosing flexibility to meet your patient’s unique clinical needs, and allows them to continue to titrate to reach maximum clinical benefit.¹*

Tablets are not shown to actual size.

*Maximum labeled dose for Orenitram is 120 mg TDD.¹

Support a TID dosing schedule

Orenitram is best tolerated TID every 8 hours with food, as this may help to reduce peak-to-trough fluctuations.¹

Breakfast
(6A-8A)

8 HOURS

Afternoon Snack
(2P-4P)

8 HOURS

Bedtime Snack
(10P-12A)

Help proactively manage and plan for expected adverse effects^1,2

Reaching a therapeutic dose may be challenging for some patients. Most discontinuations occur within the first few months and may be due to adverse events.³

See Strategies for Managing Adverse Effects >

“What I would tell someone who’s starting to titrate on Orenitram is to give yourself time to get used to the side effects, because for me it got better. There is light at the end of the tunnel.”
—An Orenitram patient

Frequently Asked Questions

United Therapeutics does not provide medical advice. Adverse event management or dosing strategies should be dealt with in accordance with the Orenitram Full Prescribing Information and your clinical judgment.

Orenitram Titration Kit

Discover how the Titration Kit may help your patient start Orenitram with confidence.

Transitioning to Orenitram

See why stable patients on parenteral prostacyclin who switch to Orenitram may transition successfully.

A Confident Start

Read about the steps you and your patient may take to help them feel confident as they begin taking Orenitram.

AE=adverse effect; BID=2 times daily; PAH=pulmonary arterial hypertension; TDD=total daily dose; TID=3 times daily.

IMPORTANT SAFETY INFORMATION

Contraindications

Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

IMPORTANT SAFETY INFORMATION

Contraindications

Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

Adverse Reactions

In the 12-week, placebo-controlled, monotherapy study, and an event-driven placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

Drug Interactions

Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

Specific Populations

Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
Safety and effectiveness of Orenitram in pediatric patients have not been established.
Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

INDICATION

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

OREISIhcpOCT19

Please see Full Prescribing Information and Patient Information for Orenitram.

For additional information, call 1-877-UNITHER (1-877-864-8437).

References: 1. Orenitram [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2023. 2. Rahaghi FF, Feldman JP, Allen RP, et al. Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. Pulm Circ. 2017;7(1):167-174. 3. Data on file. United Therapeutics Corporation. Research Triangle Park, NC.

Dosing to Meet
Individualized Needs